Chemomab Therapeutics Ltd.
NASDAQ Capital MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Adi Mor George
- Full Time Employees
- 20
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- Building 7 Tel Aviv Israel 6158002
- IPO Date
- Feb 12, 2019
- CIK
- 0001534248
- Website
- chemomab.com
- Similar Companies
- Business
- Chemomab Therapeutics Ltd. (Nasdaq: CMMB) is a clinical-stage biotechnology company focused on the discovery, development, and commercialization of innovative therapeutics targeting fibro-inflammatory diseases with high unmet medical needs. Founded in 2011 and headquartered in Tel Aviv, Israel, the company develops monoclonal antibodies that neutralize key mediators of fibrosis and inflammation, primarily through its lead product candidate nebokitug (CM-101), a first-in-class humanized antibody that binds and blocks CCL24 activity to interrupt the fibro-inflammatory cycle; nebokitug targets primary sclerosing cholangitis (PSC), systemic sclerosis (SSc), and other severe fibrotic conditions affecting the liver, skin, lungs, and related tissues, with demonstrated efficacy in preclinical models and positive clinical data from multiple trials including improvements in liver injury, inflammation, and fibrosis biomarkers. The company operates primarily in the United States and Israel, with clinical programs advancing under U.S. FDA oversight and an open IND for SSc, serving patient populations suffering from rare and life-threatening fibrotic disorders lacking approved therapies. Recent developments include the successful completion of the Phase 2 SPRING trial in PSC, reporting positive 15-week and 48-week data in 2025 that met primary safety endpoints and showed sustained biomarker improvements in patients with moderate-to-advanced disease; alignment with the FDA in February 2025 on a streamlined Phase 3 registration pathway via a single pivotal, clinical events-driven trial without requiring liver biopsies or confirmatory studies, positioning nebokitug as a potential first FDA-approved therapy for PSC. Chemomab continues preparations for this Phase 3 program while pursuing strategic partnerships, with active discussions underway as of mid-2025 for collaboration on advancement to registration; additional milestones encompass presentations of positive nebokitug data at major 2025 conferences including DDW and EASL, alongside new patent awards strengthening intellectual property protection for the asset. The company maintains a cash position supporting ongoing operations, with a focus on value-creating options to progress its pipeline amid limited internal resources for large-scale trials.
Chemomab Therapeutics Announces First Quarter 2026 Financial Results and Provides Corporate Update
Chemomab Therapeutics Announces Year End and Fourth Quarter 2025 Financial Results and Provides a Corporate Update
Chemomab Therapeutics to Participate in Oppenheimer 36th Annual Healthcare Life Sciences Conference
Chemomab Therapeutics Ltd. Sponsored ADR (NASDAQ:CMMB) Sees Significant Growth in Short Interest
Chemomab Therapeutics Announces Nebokitug Phase 2 SPRING Trial Results in Primary Sclerosing Cholangitis Published in the American Journal of Gastroenterology
Chemomab to Participate in Oppenheimer's Movers in Rare Disease Summit
Chemomab Therapeutics Announces Third Quarter 2025 Financial Results and Provides Corporate Update
Chemomab Announces Multiple Presentations at AASLD The Liver Meeting® 2025 Featuring Clinical Data from the Nebokitug Phase 2 Trial in Primary Sclerosing Cholangitis
Best Momentum Stocks to Buy for Oct. 23
New Strong Buy Stocks for Oct. 23: MQ, GES and More
Chemomab Therapeutics to Present at H.C. Wainwright 27th Annual Global Investment Conference
CMMB, with P&G Support, Responds to Deadly Cholera and Hunger Crisis in South Sudan
Chemomab Therapeutics Announces Second Quarter 2025 Financial Results and Provides Corporate Update
Chemomab Announces Oral Presentation of Positive Nebokitug Phase 2 Clinical Data in Primary Sclerosing Cholangitis at BSG Live'25
Chemomab Reports Positive Feedback From Two Recent FDA Meetings Supporting Phase 3 Advancement of Nebokitug in Primary Sclerosing Cholangitis
Chemomab Announces New Patent Awards for Its First-in-Class Agent Nebokitug that is Positioned to Potentially Become the First Approved Drug for Primary Sclerosing Cholangitis
Chemomab Therapeutics Announces First Quarter 2025 Financial Results and Provides Corporate Update
Chemomab Announces Presentation of Positive Nebokitug Phase 2 Clinical Data in Primary Sclerosing Cholangitis in Distinguished Plenary Session at DDW 2025
Chemomab Reports New Positive Clinical Data at EASL 2025 Supporting Nebokitug's Impact in Primary Sclerosing Cholangitis and Related Diseases
Chemomab Therapeutics to Present Nebokitug Clinical Data at Upcoming Scientific Conferences